Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio
This article was originally published in The Pink Sheet Daily
Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.
You may also be interested in...
The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.
Our survey of news and notes from the third day of the BIO 2013 conference includes insights from panel discussions about the environments for licensing deals and Alzheimer’s disease research, an interview with a Roche exec about the company’s partnering strategy, and news about a crowdfunding portal that will connect VCs and companies with accredited individual investors.
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.